Research Study

A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer
Principal Investigator 
Sasha Smiljanic

Overview

Body Locations and Systems 
Lung Cancer
Disorders and Conditions 
Lung Cancer
ClinicalTrials.gov# 
NCT03322566
Status 
Closed for Recruitment
Study Start/End 
Jan 18, 2018 to Dec 30, 2022
Locations 
Lions Gate Hospital
Name/Title 
Valla Sahraei, Clinical Trials Coordinator
Phone 
604-988-3131 ext.4934
Email Address 
valla.sahraei@vch.ca
Purpose of Study 

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat alone or with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.